Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and pd-l1 cps of 10 or more

HIGHLIGHTS

• who: Huide Zhu and Hongfu Cai from the Central South University, China have published the paper: Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More, in the Journal: (JOURNAL)
• what: The KEYNOTE-590 trial was conducted to evaluate the efficacy of pembrolizumab plus chemotherapy vs. chemotherapy alone for first-line treatment of advanced ESCC. Currently, economic research on pembrolizumab for cancer treatment is very limited, with the majority of studies focusing on colorectal cancer or . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.